Literature DB >> 12843097

Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates.

Rafael E Campo1, Paola N Lichtenberger, Isabella Rosa, German Suarez, Fernando A Rivera, Allan E Rodriguez, Dushyantha T Jayaweera, Natalie A Wahlay, Michael A Kolber.   

Abstract

Genotypic resistance to all antiretroviral classes was widespread among human immunodeficiency virus type 1 isolates failing therapy. Resistance to nonnucleoside reverse transcriptase inhibitors was found most frequently and resistance to protease inhibitors was found least frequently, most likely due to differences in the number of enzymatic amino acid substitutions leading to resistance to each particular drug class.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12843097      PMCID： PMC165347          DOI： 10.1128/JCM.41.7.3376-3378.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype.

Authors:  C Verhofstede; F V Wanzeele; B Van Der Gucht; N De Cabooter; J Plum
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

2.  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.

Authors:  Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo Viciana; Juan González; Pere Domingo; Charles Boucher; C Rey-Joly; Bonaventura Clotet
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

3.  HIV-1 drug resistance in newly infected individuals.

Authors:  D Boden; A Hurley; L Zhang; Y Cao; Y Guo; E Jones; J Tsay; J Ip; C Farthing; K Limoli; N Parkin; M Markowitz
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

Review 4.  Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing.

Authors:  J G García-Lerma; W Heneine
Journal:  J Clin Virol       Date:  2001-06       Impact factor: 3.168

5.  Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy.

Authors:  M Birk; V Svedhem; A Sönnerborg
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

6.  Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.

Authors:  P Clevenbergh; J Durant; P Halfon; P del Giudice; V Mondain; N Montagne; J M Schapiro; C A Boucher; P Dellamonica
Journal:  Antivir Ther       Date:  2000-03

7.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

8.  Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

Authors:  H Weinstock; R Respess; W Heneine; C J Petropoulos; N S Hellmann; C C Luo; C P Pau; T Woods; M Gwinn; J Kaplan
Journal:  J Infect Dis       Date:  2000-06-13       Impact factor: 5.226

9.  Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

10.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245
View more
  2 in total

Review 1.  Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.

Authors:  Sonya J Snedecor; Lavanya Sudharshan; Katherine Nedrow; Abhijeet Bhanegaonkar; Kit N Simpson; Seema Haider; Richard Chambers; Charles Craig; Jennifer Stephens
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-08       Impact factor: 2.205

2.  An update on the use of Atripla in the treatment of HIV in the United States.

Authors:  Michael A Horberg; Daniel B Klein
Journal:  HIV AIDS (Auckl)       Date:  2010-06-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.